AI performs as well as medical specialists in analyzing lung disease
The AI suggested that the red area is idiopathic pulmonary fibrosis and blue area is non-idiopathic pulmonary fibrosis.
Credit: Tosei General Hospital, Reiko Matsushita
A Nagoya University research group has developed an AI algorithm that accurately and quickly diagnoses idiopathic pulmonary fibrosis, a lung disease. The algorithm makes its diagnosis based only on information from non-invasive examinations, including lung images and medical information collected during daily medical care.
Doctors have waited a long time for an early means of diagnosing idiopathic pulmonary fibrosis, a potentially fatal disease that can scar a person’s lungs. Except for drugs that can delay the disease’s progression, established therapies do not exist. Since doctors face many difficulties diagnosing the disease, they often have to request a specialist diagnosis. In addition, many of the diagnostic techniques, such as lung biopsy, are highly invasive. These investigative measures may exacerbate the disease, increasing a patient’s risk of dying.
Taiki Furukawa, Assistant Professor of the Nagoya University Hospital, in collaboration with RIKEN and Tosei General Hospital, has developed a new technology to diagnose idiopathic pulmonary fibrosis. Using artificial intelligence (AI), the group analyzed medical data from patients in Tosei General Hospital’s interstitial pneumonia treatment facility, collected during normal care. They found that their AI diagnosed idiopathic pulmonary fibrosis with a similar level of accuracy as a human specialist. They published their results in the journal Respirology.
Despite finding that their AI performed just as well as experts, the team stress that they do not see it as replacing medical professionals. Instead, they hope that specialists will use AI in medical treatment to ensure that they do not miss opportunities for early treatment. Its use would also avoid invasive procedures, such as lung biopsies, which could save lives.
“Idiopathic pulmonary fibrosis has a very poor prognosis among lung diseases”, Furukawa says. “It has been difficult to diagnose even for general respiratory physicians. The diagnostic AI developed in this study would allow any hospital to get a diagnosis equivalent to that of a specialist. For idiopathic pulmonary fibrosis, the developed diagnostic AI is useful as a screening tool and may lead to personalized medicine by collaborating with medical specialists.”
Furukawa is excited about the possibilities: “The practical application of diagnostic AI and collaborative diagnosis with specialists may lead to a more accurate diagnosis and treatment. We expect it to revolutionize medical care.”
This study was supported by JSPS KAKENHI, Grant/Award Number: JP19110253; The Hori Science and Arts Foundation; The Japanese Respiratory Foundation.
Journal: Respirology
DOI: 10.1111/resp.14310
Article Title: A comprehensible machine learning tool to differentially diagnose idiopathic pulmonary fibrosis from other chronic interstitial lung diseases
Article Publication Date: 13-Jun-2022
Media Contact
Matthew Coslett
Nagoya University
kouho-en@adm.nagoya-u.ac.jp
Office: +81 (0)52-747-6862
All latest news from the category: Medical Engineering
The development of medical equipment, products and technical procedures is characterized by high research and development costs in a variety of fields related to the study of human medicine.
innovations-report provides informative and stimulating reports and articles on topics ranging from imaging processes, cell and tissue techniques, optical techniques, implants, orthopedic aids, clinical and medical office equipment, dialysis systems and x-ray/radiation monitoring devices to endoscopy, ultrasound, surgical techniques, and dental materials.
Newest articles
A new class of cosmic X-ray sources discovered
An international team of astronomers, led by researchers from the Astronomical Observatory of the University of Warsaw, have identified a new class of cosmic X-ray sources. The findings have been…
An open solution to improving research reproducibility
Academic and industry scientists collaborate on a new method to characterize research antibodies. Structural Genomics Consortium researchers at The Neuro (Montreal Neurological Institute-Hospital) of McGill University, in collaboration with scientists…
Living in the deep, dark, slow lane
Insights from the first global appraisal of microbiomes in earth’s subsurface environments. Which microbes thrive below us in darkness – in gold mines, in aquifers, in deep boreholes in the…